Clinical Trials Sponsored by Turning Point

Total 1566 results

Turning Point Therapeutics, Inc.

Recruiting

A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

Advanced Solid Tumor | Metastatic Solid Tumor

United States
Turning Point Therapeutics, Inc.

Recruiting

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Lymphoma | Locally Advanced Solid Tumors | Metastatic Solid Tumors | Primary CNS Tumors

United States, Korea, Republic of, Spain, Singapore, Taiwan, Australia, Italy, Canada, France, Denmark, United Kingdom
Turning Point Therapeutics, Inc.

Completed

Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors

Advanced Solid Tumor

United States
Turning Point Therapeutics, Inc.

Terminated

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Advanced Solid Tumor | Metastatic Solid Tumor | KRAS Mutation-Related Tumors

United States
Turning Point Therapeutics, Inc.

Active, not recruiting

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1)

Advanced Solid Tumor | Metastatic Solid Tumors | MET Gene Alterations

United States, France, Korea, Democratic People's Republic of, Korea, Republic of, Spain
Monash University
Turning Point

Completed

Brain Exercise and Addiction Trial (BEAT)

Cannabis Use Disorder, Moderate | Cannabis Use Disorder, Severe

Australia
Turning Point Therapeutics, Inc.

Withdrawn

A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients

Metastatic Solid Tumor | Locally Advanced Solid Tumor

United States, Spain
Turning Point Therapeutics, Inc.

Terminated

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Medullary Thyroid Cancer | RET Gene Mutation

United States, Korea, Republic of
Turning Point Therapeutics, Inc.

Terminated

A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC

Non-Small Cell Lung Cancer | NSCLC | Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | ALK Gene Mutation

United States, Australia, Korea, Republic of
Turning Point
Monash University; Eastern Health

Recruiting

AAT-APP+: A Novel Brain-training App to Reduce Drinking

Alcohol Use Disorder

Australia
Turning Point
Monash University; Eastern Health

Completed

Increasing Knowledge of Alcohol as a Risk Factor for Breast Cancer Among Women Attending Breast Screening Services (Health4Her)

Alcohol Consumption | Health Knowledge, Attitudes, Practice

Australia
Turning Point
Monash University; Deakin University

Completed

Can Cognitive-bias Modification Training During Inpatient Alcohol Detoxification Reduce Relapse Rates Post-discharge?

Alcohol Dependence

Australia
Instituto Oncológico Dr Rosell
Turning Point Therapeutics, Inc.

Recruiting

Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients (TOTEM)

Nsclc

Spain
Turning Point
Monash University; Eastern Health; Deakin University

Completed

A Telephone-delievered Intervention to Reduce Methamphetamine Use (R2C-M)

Methamphetamine Use Disorder

Australia
Turning Point Therapeutics, Inc.
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Locally Advanced Solid Tumors | Metastatic Solid Tumors

United States, China, Japan, Australia, Belgium, Canada, Denmark, France, Germany, Hong Kong, Hungary, Italy, Korea, Democratic People's Republic of, Korea, Republic of, Netherlands, Poland, Singapore, Spain, Taiwan, United Kingdom
Point Biomedical

Completed

Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease

Coronary Artery Disease

United States
Point Biomedical

Completed

Familiarization and Safety Study of PB127 Ultrasound Contrast Agent

Coronary Artery Disease

United States
Point Biomedical

Terminated

Safety and Efficacy Study of PB127 Ultrasound Contrast Agent for Diagnosis of Coronary Artery Disease (POINT II)

Coronary Artery Disease

United States
Point Biomedical

Completed

Dose Finding Study of PB127 Ultrasound Contrast Agent in Healthy Volunteers and Patients With Coronary Artery Disease

Coronary Artery Disease | Healthy

United States
Point Therapeutics

Completed

Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer

Lung Cancer

United States
Point Therapeutics

Terminated

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Neoplasms, Lung | Neoplasms, Pulmonary

United States
Point Therapeutics

Terminated

Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Carcinoma, Non-Small Cell Lung

United States
Point Therapeutics

Terminated

Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas

Adenocarcinoma | Neoplasm Metastasis | Pancreatic Cancer

United States
POINT Biopharma

Active, not recruiting

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

Soft Tissue Sarcoma | Colorectal Cancer | Esophageal Cancer | Cholangiocarcinoma | Head and Neck Squamous Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Melanoma (Skin)

United States, Canada
Point Biomedical

Completed

Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease 007

Coronary Artery Disease

United States
Point Biomedical

Terminated

Long-Term Follow-up Study of Patients Who Received PB127 Ultrasound Imaging Agent

Coronary Artery Disease

United States
Point Biomedical

Terminated

Evaluation and Optimization of PB127 Myocardial Perfusion Echocardiography on Ultrasound Systems

Coronary Artery Disease | Healthy

United States
Point Therapeutics

Completed

Study of Talabostat and Cisplatin in Advanced Melanoma

Melanoma | Skin Cancer

United States
Point Therapeutics

Completed

Study of Talabostat in Advanced Melanoma

Melanoma | Skin Cancer

United States
Turning Point
Monash University; Eastern Health; BreastScreen Victoria; Lifepool; Shades of Pink

Completed

An Electronic Brief Alcohol Intervention for Women Attending a Breast Screening Service (Health4Her)

Alcohol Drinking | Health Knowledge, Attitudes, Practice

Australia
High Point University

Recruiting

The Effect of Combining Pain Neuroscience Education and Transcranial Direct Current Stimulation on Pain Catastrophizing, Kinesiophobia, and Pain in Patients With Chronic Low Back Pain

Chronic Low-back Pain | Catastrophizing Pain | Kinesiophobia

United States
High Point University

Terminated

The Diagnostic Accuracy of the Clinical Examination

Musculoskeletal Pain | Musculoskeletal Injury

United States
High Point University

Completed

Real-time Optimized Biofeedback Utilizing Sport Techniques (ROBUST)

Knee Injuries
High Point University

Completed

Utilizing the Trunk as a Proximal Lever to Strengthen the Hip Musculature and Alter Lower Extremity Function

Patellofemoral Pain Syndrome

United States
High Point University

Completed

Conservative Management of Femoroacetabular Impingement

Femoroacetabular Impingement

United States
High Point University

Completed

Do Common Physical Tests Predict Injury or Performance (TEAM)

Lower Extremity Musculoskeletal Injury

United States
Cell>Point LLC

Completed

A Single Center Study to Establish the Imaging Protocol of 99mTc-EC-DG in Evaluating the Presence and Severity of Coronary Artery Disease (CAD)

Coronary Artery Disease

United States
Cell>Point LLC

Unknown

Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)

Coronary Artery Disease

United States
Cell>Point LLC

Active, not recruiting

A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer

Lung Cancer

United States
High Point University

Completed

Benefits of Traditional and Golf-specific Resistance Training in Amateur Female Golfers

Improved Performance in Amateur Female Golfers (MESH Term: Body Composition)

United States
High Point University

Completed

Neurocognitive Visual Reaction Training

Reaction Time

United States
Turning Point
Monash University; Eastern Health; National Centre for Clinical Research on Emerging...

Recruiting

Intranasal Oxytocin for Methamphetamine Withdrawal in Women (mOXY)

Methamphetamine Use Disorder

Australia
Turning Point
St Vincent's Hospital Melbourne; Monash Health; Uniting Vic Tas; Star Health; Odyssey...

Active, not recruiting

AAT-App Outpatient Trial (AAT-App)

Alcohol Use Disorder (AUD)

Australia
Abbott Point of Care

Not yet recruiting

Method Comparison Study for Measuring Potassium (K) and Ionized Calcium (iCa) in Blood

Potassium (K) and Ionized Calcium (iCa) in Capillary Whole Blood
Zero Point Five Therapeutics

Not yet recruiting

Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Effectiveness and Safety of ZP5-9676 for the Treatment of Soil Transmitted Helminthiasis (STH)

Soil-Transmitted Helminthiasis (STH)

Brazil, Ghana
Oyster Point Pharma, Inc.

Terminated

A Study Evaluating the Safety of the Nasal Pump

Dry Eye | Kerato Conjunctivitis Sicca

United States
Oyster Point Pharma, Inc.

Completed

Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study)

Dry Eye Disease

Mexico
Oyster Point Pharma, Inc.

Completed

Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)

Dry Eye Disease

United States
Oyster Point Pharma, Inc.

Completed

Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

Dry Eye Disease (DED)

United States
High Point Pharmaceuticals, LLC.

Terminated

A Safety and Efficacy Study of HPP404 on Weight Loss in Overweight or Obese Subjects

Obesity | Overweight

United States

Clinical Trials Sponsored by Turning Point

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations